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electrical stimulation of the P6 antiemetic point, in patients having highly
emetic cytotoxic drugs
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The introduction of ondansetron has revolutionised the treat-
ment of nausea and vomiting which frequently follows cispla-
tin and other drugs used in the treatment of cancer. How-
ever, there remain some patients for whom this 5 HT3
antagonist offers only a partial alleviation of symptoms, par-
ticularly on the 3rd and 4th days of treatment. Even when
there may be no vomiting, some patients still remain
nauseated.
We have demonstrated that stimulation of the P6 acupunc-
ture point (Neiguan) enhances the antiemetic action of the
older group of drugs such as metoclopramide, phenothiazines
and cyclizine (Dundee et al., 1989b). This applies to both
invasive (needling) and non-invasive (transcutaneous elec-
trical) stimulation (Dundee et al., 1991). We here report
a randomised crossover study in 16 hospitalised patients
comparing the degree of sickness over a 5 day period when
the chemotherapy was accompanied by ondansetron or by
ondansetron and transcutaneous electrical stimulation of P6
(TCES).
Transcutaneous stimulation ofP6 (TCES)
The P6 (Neiguan) point is located 2 cun (1 cun or Chinese
inch being equal to the width of the individual's thumb)
proximal to the distal wrist crease, between the tendons of
palmaris longus and flexor carpi radialis.
Our custom built stimulator is a simplification of the com-
mercially available 'Mini-Tens' unit, generating a biphasic,
asymmetrical direct current with a frequency of 10-15 Hz.
The two output leads are attached via 'crocodile' clips to
surface ECG type disposal electrodes. A 'Unilect' silver
chloride electrode is placed on the P6 (Neiguan) point and
connected to the negative polarity output. In order to com-
plete the circuit the positive polarity output is connected to a
'Biotab' electrode located on the Hegu (large intestine (LI) 4)
point. This is located between the first and second metacarpal
bones approximately in the middle of the second metacarpal
bone on the radial side.
Methods
Patients scheduled for two courses of highly emetic chemo-
therapy were pretreated with 8 mg ondansetron IV followed
by 8 mg by mouth three times per day for 5 days. Chemo-
therapy agents included cisplatin at doses of 20 mg m-2
infused over 6-8 h daily, for 5 days often combined with
other cytotoxics and cyclophosphamide administered as a
bolus of 500-600 mg with other cytotoxic drugs as shown in
Table II. Courses were separated by a period of at least 3
weeks. In random order with one of these courses trans-
cutaneous electrical stimulation of the P6 point was carried
out on the dominant forearm as described above. The appar-
atus was operated by the patients themselves, the current
being turned up until the sensation Qi, a non-anatomically
distributed sensation radiating into the fingers and up the
forearm, was elicited. Stimulation was carried out for 5 min
every 2 h when awake.
Patients were frequently visited over these 5 days, when the
incidence of nausea and vomiting over each 24 h period was
recorded. The degree of sickness was analysed according to
the definition of an emetogenic response (Table I) as used by
others (Kris et al., 1985; Schmoll, 1989) and comparable to
that in our reported studies with acupuncture (Dundee &
Yang, 1990).
Results
There were no major side effects directly attributed to ondan-
setron although some reported constipation and headache.
Most patients found no difficulty in self stimulation of P6.
Figure 1 gives the day to day distribution of nausea scores,
severity while Table II gives the individual average overall
vomiting responses and indicates where there was a beneficial
effect from TCES. Of the 16 patients, four showed no
difference between degrees of nausea and vomiting with
Table I Scheme for grading of sickness
Response Emesis Nausea
Complete 0 None
Major response 1-2 Mild=did not interfere with everyday life
Minor response 3-5' Moderate = interfered with everyday life
Failure >5 Severe = bedridden due to nausea
Emetic episode = any vomiting productive of liquid or I to 5 dry
retches within a 5 min period.
TableII Fivedayoverall evaluationofthedegreeofemesis, defined in
terms of response, following chemotherapy in 16 patients given
ondansetron (8 mg tds) with or without transcutaneous electrical
stimulation of P6 (TCES)
Ondansetron Benefitfrom
Chemotherapy Ondansetron + TCES TCES
C Major Complete +
Cy:E:V Major Complete +
C:E Major Complete +
C:B:E Failure Minor +
C Failure Major +
Cy:V:M Complete Complete 0
C:B:E Complete Complete 0
C Minor Major +
C:E Major Complete +
Cy:A Major Complete +
C:B:E Minor Major +
C:E Major Major 0
C Complete Complete 0
C:E Major Complete +
C:E Major Complete +
C Major Complete +
C = Cisplatin; Cy = Cyclophosphamide; E = Etoposide; A = Ad-
riamycin; B = Bleomycin; M = Methotrexate; V = Vincristine.
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Figure 1 Day to day nausea scores. C Moderate; 1 B
Mild; = A None.
ondansetron alone and when combined with TCES. All of
the remaining 12 showed a preference in favour of the latter.
Using the binomial sign test this difference is highly signi-
ficant (P= 0.0005). Three of the four patients who showed
no difference in response to the two regimes had a complete
absence of sickness with both.
There were no problems in acceptance of the combined
regimes.
Discussion
Stimulation of the P6 antiemetic point by either acupuncture
or transcutaneous electrical stimulation has been practised
widely in our hospital for 4-5 years. All staff and many
patients knew why it was being used, but most were not
aware of the true nature of our study until it was completed.
The need to elicit Qi was an essential part of our technique
and excluded the use of 'dummy TCES' either in the form of
a stimulator not generating a pulse or by stimulation of a
non-acupuncture point. Furthermore there was no way in
which the person doing the assessments could be unaware of
the use of TCES.
We have accepted these limitations in our previous studies
and feel that they are more than compensated for by our
simple scoring scheme which relies heavily on what the
patient says and on the views of their attendants. While we
cannot entirely divorce ourselves from the thought that the
differences might be attributed to active patient involvement;
however well controlled randomised studies, both in anaes-
thesia (Dundee et al., 1989a) and cancer chemotherapy (Dun-
dee et al., 1989b) have shown that 'dummy' acupuncture is
ineffective as an antiemetic. Moreover, the important finding
is that, irrespective of the mode of action, our patients
benefited from the treatment.
Ondansetron has a high reputation as an antiemetic among
all our staff and it is interesting to note that incapacitating
sickness was only recorded in two patients in this study
(Table II). This differs from our experience with the older
group of conventional antiemetics (Dundee et al., 1989b).
However we have an, as yet unconfirmed, clinical impression
that its efficacy appears to wane with time.
Smith and colleagues (1990), likewise aware of some of its
limitations, have supplemented the use of ondansetron with
dexamethasone and have demonstrated additional antiemetic
activity by the steroid. Their findings are similar to ours
reported here with P6 stimulation.
Ondansetron, while effective, is an expensive drug and
since its efficacy can be increased by a simple non-expensive
technique such as transcutaneous electrical stimulation of P6
this concept is worthy of further study. Most patients, rather
than objecting to its use, like to be able to play some part,
albeit a small one, in their own treatment.
This work was generously supported by the Friends of Montgomery
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